Absci vs Biolojic Design (2026)
Absci and Biolojic Design both use machine learning to design antibodies and develop them with partners, and BiopharmaTrend's survey of AI antibody discovery names them together. They aim at different kinds of molecule. Absci designs antibodies de novo against chosen epitopes with Origin-1, tests them in its own high throughput lab and leads with ABS-201, an anti prolactin receptor antibody in a Phase 1/2a trial for pattern hair loss. Biolojic designs antibodies that do more than block a target: epitope specific agonists, conditional binders and multibodies that bind more than one target on one arm. AU-007, designed on its platform and developed by Aulos Bioscience, began dosing cancer patients in 2022, and TEV-325, partnered with Teva, entered enabling studies for atopic dermatitis and asthma in 2025. Absci suits a partner looking for new binders against hard epitopes; Biolojic suits one that needs functional or multispecific behavior designed in.
- Antibodies designed against epitopes with no known binder.
- A wet lab producing billions of protein interaction measurements a week.
- A peer reviewed 2026 paper on model performance with a stated success rate.
- ABS-201, with a half life of at least 65 days in interim data.
- Agonist and conditional antibodies designed for a specific function.
- Multibodies that bind more than one target on the same arm.
- A platform designed antibody, AU-007, in human trials since 2022.
- A partnered autoimmune program with Teva.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Absci and Biolojic Design are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Absci | Biolojic Design |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2011 | Not recorded |
| Headquarters | Vancouver, Washington | Rehovot, Israel |
| Website | absci.com | biolojic.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Absci combines its Origin-1 de novo design model with lead optimization models and an automated laboratory, and develops the antibodies it designs, led by ABS-201 in a Phase 1/2a trial, with partners such as AstraZeneca and Almirall.
Source: AI Health Index, October 2026
Biolojic Design, based in Rehovot, Israel, uses machine learning to design functional antibodies, including agonists, conditional binders and multibodies, and develops them with partners such as Aulos Bioscience and Teva and in its own pipeline.
Source: AI Health Index, October 2026
Questions buyers ask
What kind of antibodies does each design?
Absci focuses on new binders designed against a chosen epitope and tuned for developability and half life. Biolojic designs antibodies with a specific function, such as receptor agonists, conditional binders and multispecific multibodies. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
What has reached the clinic?
AU-007, designed on Biolojic's platform, began dosing cancer patients in 2022 under Aulos Bioscience. Absci's ABS-201 is in a Phase 1/2a trial that reported interim data in June 2026. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
What does each publish about its methods?
Absci names its Origin-1 model and published a 2026 mAbs paper with a measured success rate. Biolojic publishes conference posters and technical reports on its antibodies rather than peer reviewed platform papers. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 12, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
AU-007 is developed by Aulos Bioscience, and TEV-325 is partnered with Teva.